The FDA unveiled a new strategy to tackle the ongoing shortage of ADHD medications that includes streamlining the approval process for new manufacturing facilities and increasing production limits for existing manufacturers, The New York Times reported Sept. 6.
The shortage of ADHD medications has been a growing concern over the past year, with patients reporting difficulties accessing prescriptions and experiencing disruptions in treatment regimens. The FDA's new plan is designed to address these challenges by boosting production limits and ensuring a more stable supply of the drugs.
The plan also includes improved monitoring of drug availability and more transparent reporting from drug manufacturers about production and distribution challenges.
Read more about the plan here.